Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, is pleased to announce the completion of a private placement of approximately $137 million worth of its ordinary shares. The Shares, par value $0.01 per share, were purchased at a price of $11.57 per share and are expected to be delivered from previously issued treasury shares held by Alvotech’s subsidiary, Alvotech Manco ehf. With this private placement, Alvotech is able to provide patients worldwide with access to life-saving biosimilar medicines.
The Shares were offered exclusively to professional clients and eligible counterparties in Iceland, in compliance with European Parliament and Council Directive 2014/65/EC and local regulations. This directed offering is a great opportunity to access a sought-after asset, while following the customs and laws of the region.
Are you looking for an exciting opportunity to invest in something new? If so, we have just the thing for you! We are offering a limited number of shares that are not registered under the United States Securities Act, as amended, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. Don’t miss out on this chance to make a smart investment!
About Alvotech
Alvotech is a biotech leader in the biosimilar space, providing high quality, cost-effective treatments for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer. With a fully integrated approach, Alvotech has formed a network of strategic commercial partnerships around the world, including Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, Cipla/Cipla Gulf/Cipla Med Pro, JAMP Pharma Corporation, Yangtze River Pharmaceutical (Group) Co., Ltd, DKSH, YAS Holding LLC, Abdi Ibrahim, Kamada Ltd, Mega Labs, Stein, Libbs, Tuteur and Saval, and Lotus Pharmaceuticals Co., Ltd. Alvotech, founded by Robert Wessman, is committed to providing access to safe, effective biosimilar medicines to patients worldwide.